Abstract
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a major cause of mortality and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS HAT has unacceptable side-effects with an overall mortality of 5%. This review discusses the issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility of new therapies for treating late-stage disease.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Africa
-
Animals
-
Central Nervous System Protozoal Infections* / diagnosis
-
Central Nervous System Protozoal Infections* / drug therapy
-
Central Nervous System Protozoal Infections* / pathology
-
Central Nervous System Protozoal Infections* / physiopathology
-
Humans
-
Trypanocidal Agents / therapeutic use
-
Trypanosoma brucei brucei / metabolism
-
Trypanosoma brucei brucei / ultrastructure
-
Trypanosomiasis, African* / diagnosis
-
Trypanosomiasis, African* / drug therapy
-
Trypanosomiasis, African* / pathology
-
Trypanosomiasis, African* / physiopathology